Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 4/20 | 0.45 |
| ▸ | ABL1 | P00519 | 4/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | ABL2 | P42684 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4899946 | 0.75 | POLB (0.42) | TRPV1KMT2APOLB | |
| SCHEMBL7418748 | 0.72 | KMT2A (0.48) | TRPV1PTGS2KMT2A | |
| SCHEMBL4908957 | 0.71 | PDE4B (0.50) | TRPV1KMT2AHTT | |
| SCHEMBL8297908 | 0.71 | KDR (0.50) | SRCABL1EGFRKDR | |
| SCHEMBL4908609 | 0.70 | IGF1R (0.62) | SRC | |
| SCHEMBL14183645 | 0.69 | IGF1R (0.41) | TRPV1KMT2ANPSR1HTT | |
| SCHEMBL4907327 | 0.68 | TP53 (0.56) | KMT2ANPSR1HTT | |
| SCHEMBL4909767 | 0.68 | FBP1 (0.49) | ABL1EGFRABL2KDRRAPGEF4 | |
| SCHEMBL1298561 | 0.68 | JAK2 (0.47) | SRCABL1EGFRABL2KDR | |
| SCHEMBL21967388 | 0.67 | FLT3 (0.52) | SRCABL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYNTOVIA, INC. (US) | 2008-05-15 | — | — | US | claimed |
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYNTOVIA, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYNTOVIA, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYNTOVIA, INC. (US) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP7, API5, CASP5 | SRC 3361/4885ABL1 715/4885EGFR 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.